By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...
Stories by SWNS on MSN
Prostate cancer treatment breakthrough could boost survival rates
A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research.
SurvivorNet on MSN
ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer
Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...
Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...
Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...
Dr. Glenn Bauman, Scientist at LHSCRI and Radiation Oncologist at London Health Sciences Centre (LHSC), stands in front of the positron emission tomography (PET) scanner. LONDON, ON – A multicentre ...
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent ...
Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior ...
Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine ...
How much do healthy lifestyle habits, such as diet and exercise, matter after a cancer diagnosis? Adopting healthy lifestyle ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results